51 F
New York
Tuesday, April 20, 2021

Trump Receives Gilead’s [NASDAQ: GILD] Remdesivir As Treatment For COVID-19 Infection

Must read

IAA [NYSE: IAA] Announces Expansion of Delivery Services in the UK

IAA, Inc. disclosed that its UK-based business unit has decided to expand its vehicle delivery services for its buyers. This expansion decision has...

ICON [NASDAQ: ICLR] Secures Multiple Categories in 2021 CRO Leadership Awards

ICON Public Limited Company has disclosed that it has won multiple categories in the annual CRO Leadership Awards. This is another greatest achievement...

Equinox Announces Sale of Pilar Gold Mine

Equinox Gold Corp. revealed Monday that it has decided to sell its Pilar Gold Mine in Brazil to Pilar Gold Inc. The firm...

OpGen [NASDAQ: OPGN] Announces Strategic Collaboration New York State Department of Health

OpGen, Inc. revealed that it has entered into a strategic collaboration deal with the New York State Department of Health. The focus of...

Gilead Sciences, Inc’s [NASDAQ: GILD] remdesivir has been given to President Donald Trump at Walter Reed National Military Medical Center on Friday.

It has been revealed that the white house doctors have recommended the experimental drug of Gilead to treat the COVID-19 infection of President Donald Trump.

White House Physician Sean Conley has released an update on the health of President Donald Trump. Sean Conley disclosed that President Trump is doing well and he doesn’t require any supplemental oxygen.

But the doctors have chosen the Gilead Sciences’ remdesivir to treat his COVID-19 infection. Trump has received the first dose and he is resting comfortably.

Shares of Gilead Sciences [NASDAQ: GILD] traded down 1.82% as it lost -1.15 during the trading session of Friday. It has a closing price of $62.17. GILD had a trading volume of 7.76 million as compared to the average volume of 8.70 million.

In the past 52-weeks of trading, this company’s share fluctuated between the low range of $60.89 and a high range of $85.97. GILD has moved up 2.10% from its 52-weeks low and moved down -27.68% from its 52-weeks high.

Looking at its profitability, this company has a current ratio of $2.30. GILD market capitalization has remained high, hitting $77.94 billion at the time of writing.

Gilead has committed to combat the spread of coronavirus by increasing the production of antiviral drug remdesivir.

The company has donated 1.5 million vials of Veklury (remdesivir) and provided clinical drug supply at no cost for evaluation as an investigational agent in clinical trials around the world. 

President Donald Trump has revealed on Friday that he and his wife Melania Trump has contracted coronavirus. Trump administration has earlier gave an emergency use authorization to Gilead’s remdesivir after it showed the positive results in treating COVID-19 patients.

More articles

Latest article

Why Mer Telemanagement [NASDAQ: MTSL] Skyrocketed on Friday?

Shares of Mer Telemanagement Solutions Ltd skyrocketed during the trading session of Friday. The strong performance of the firm has indicated the positive...

Largo Resources Gets Approval for Listing on Nasdaq Stock Exchange

Largo Resources disclosed that it has finally obtained authorization from Nasdaq Stock Market LLC. As per the approval, the firm will now eligible to...

Aurora Mobile [NASDAQ: JG] Inks Agreement with Wanda Film

Aurora Mobile Limited disclosed Thursday that it has inked an agreement with Wanda Film Holding Co Ltd. Since its inception, Aurora Mobile has...

Brady [NYSE: BRC] Commence Tender Offer to Buy Nordic ID Oyj

Brady Corporation has inked an agreement with Nordic ID for its acquisition. The firm has commenced the tender offering to buy all the...

Cinedigm [NASDAQ: CIDM] Achieve Record Subscription and Ad-Supported User Growth Milestones

Shares of Cinedigm Corp. skyrocketed 19.30% after the firm reported the update about the subscription. The firm has achieved the best ever achievement...

Aurora Mobile [NASDAQ: JG] Signs Partnership Agreement with Yivi

Aurora Mobile Limited revealed that it has inked a collaboration deal with Hangzhou Yivi Intelligent Technology Co., LTD. (Yivi). Yivi and Aurora both...

Total [NYSE: TOT] Join Forces with Siemens Energy to Reduce LNG Related Emissions

Total SE has joined forces with Siemens Energy to explore the solution for the reduction of CO2 emissions. The firms have inked a...

Kaixin [NASDAQ: KXIN] Signs Cooperation Agreement with Jingdong

Kaixin Auto Holdings declared Monday that it has inked a deal with Jingdong Century Trade Limited. The agreement is the collaboration agreement between...